穿戴式註射器市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球穿戴式註射器市场规模达 90 亿美元，预计 2025 年至 2034 年复合年增长率为 12.3%。慢性病盛行率的不断上升、技术的不断进步以及对创新药物输送系统日益增长的需求正在推动市场成长。随着医疗保健系统转向以患者为中心的模式，穿戴式註射器正成为有效管理慢性病的重要工具。这些设备提供了一种无缝且便利的用药方式，提高了患者的依从性和治疗效果。

全球医疗保健产业正在经历范式转变，强调个人化医疗、家庭治疗和数位医疗保健解决方案。随着糖尿病、心血管疾病和自体免疫疾病等慢性疾病负担的不断增加，对高效且使用者友好的药物传递系统的需求变得越来越重要。穿戴式註射器消除了频繁去医院的麻烦，使患者能够精确地自行用药。便利性、提高依从性和减少对医疗设施的依赖是推动广泛采用的关键因素。此外，製药公司正大力投资开发整合智慧技术的先进穿戴式註射器，进一步提升病患体验。无线连接的整合实现了远端监控，为医疗保健专业人员提供有关治疗依从性和患者反应的即时资料。

市场主要分为两类：离体注射器和体内注射器。 2023 年体内注射器市场规模将达 81 亿美元，预计复合年增长率为 13.5%。这些设备使患者能够独立服用药物，减少对护理人员的依赖并提高生活品质。需要长期治疗慢性病的人数不断增加，大大增加了对体内注射器的需求。它们能够提供精确的剂量、减轻不适并增强治疗依从性，使其成为患者和医疗保健提供者的首选。

根据注射输送类型，穿戴式註射器市场进一步分为程序输送和推注输送。 2024 年程序化给药领域的价值为 46 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 11.7%。程序化给药系统经过专门设计，可确保长期准确给药，是需要持续用药的患者的理想选择。这些系统减轻了传统手动注射方法中剂量不足或过量的风险，改善了整体治疗效果。人们对精准医疗和针对特定患者的药物治疗方案的日益关注，推动了程序化输送可穿戴注射器的采用。

美国穿戴式註射器市场价值预计到 2024 年将达到 30 亿美元，预计将大幅成长。糖尿病、肥胖症和关节炎等慢性疾病发病率的上升推动了对自我给药系统的需求。穿戴式註射器中智慧技术的整合透过实现即时监控和远端依从性追踪彻底改变了患者护理。随着医疗保健提供者优先考虑以患者为中心的解决方案，对智慧和互联药物输送设备的需求持续上升。随着製药和医疗技术公司对尖端创新的投资，美国市场有望在塑造全球穿戴式註射器的未来方面发挥关键作用。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性病发生率不断上升
    • 转向居家医疗保健
    • 生物製剂需求不断成长
    • 患者对微创设备的偏好
    • 全球人口老化
  • 产业陷阱与挑战
    • 穿戴式註射器成本高
    • 技术和设计挑战
• 成长潜力分析
• 技术进步
• 监管格局
• 比较分析：患者对手持式自动注射器与穿戴式大容量注射器的偏好
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 差距分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 体内註射器
• 离体注射器

第六章：市场估计与预测：按设备类型，2021 - 2034 年

• 主要趋势
• 可编程穿戴式註射器
• 不可编程穿戴式註射器

第七章：市场估计与预测：按註射输送类型，2021 - 2034 年

• 主要趋势
• 计划交付
• 推注给药

第八章：市场估计与预测：按使用类型，2021 - 2034 年

• 主要趋势
• 免洗可穿戴注射器
• 可重复使用的穿戴式註射器

第九章：市场估计与预测：按技术，2021 - 2034 年

• 主要趋势
• 基于 Spring
• 马达驱动
• 扩充电池
• 旋转泵
• 其他技术

第 10 章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 糖尿病
• 心血管疾病
• 肿瘤学
• 自体免疫疾病
• 传染病
• 其他应用

第 11 章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 居家照护环境
• 医院和诊所
• 门诊手术中心

第 12 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十三章：公司简介

• Amgen
• Bayer
• Becton Dickinson (BD)
• CeQur
• Eli Lilly and Company
• Enable Injections
• Eoflow
• Gerresheimer
• Insulet
• Medtronic
• novo nordisk
• Roche
• TANDEM Diabetes Care
• Valeritas
• West
• Ypsomed Selfcare Solutions

The Global Wearable Injectors Market reached USD 9 billion in 2024 and is projected to witness a CAGR of 12.3% from 2025 to 2034. The increasing prevalence of chronic diseases, continuous technological advancements, and the rising demand for innovative drug delivery systems are fueling market growth. With healthcare systems shifting toward patient-centric models, wearable injectors are emerging as essential tools for managing chronic conditions efficiently. These devices offer a seamless and convenient way to administer medications, improving patient compliance and treatment efficacy.

The global healthcare industry is experiencing a paradigm shift, emphasizing personalized medicine, home-based treatments, and digital healthcare solutions. As the burden of chronic diseases such as diabetes, cardiovascular disorders, and autoimmune diseases continues to rise, the need for efficient and user-friendly drug delivery systems is becoming more critical. Wearable injectors eliminate the hassle of frequent hospital visits, allowing patients to self-administer medications with precision. Convenience, improved adherence, and reduced dependency on healthcare facilities are key factors driving widespread adoption. Additionally, pharmaceutical companies are heavily investing in the development of advanced wearable injectors with integrated smart technology, further enhancing the patient experience. The integration of wireless connectivity enables remote monitoring, providing healthcare professionals with real-time data on treatment adherence and patient response.

The market is segmented into two main categories: off-body injectors and on-body injectors. The on-body injectors segment accounted for USD 8.1 billion in 2023, with an expected CAGR of 13.5%. These devices empower patients to administer their medications independently, reducing reliance on caregivers and improving quality of life. The growing number of individuals requiring long-term treatment for chronic illnesses is significantly boosting demand for on-body injectors. Their ability to provide precise dosing, reduce discomfort, and enhance therapy adherence makes them a preferred choice for both patients and healthcare providers.

The wearable injectors market is further categorized based on injection delivery type into programmed delivery and bolus delivery. The programmed delivery segment was valued at USD 4.6 billion in 2024 and is anticipated to grow at a CAGR of 11.7% between 2025 and 2034. Programmed delivery systems are specifically designed to ensure accurate dosing over time, making them ideal for patients requiring continuous medication administration. These systems mitigate the risks of underdosing or overdosing associated with traditional manual injection methods, improving overall treatment outcomes. The increasing focus on precision medicine and patient-specific drug regimens is propelling the adoption of programmed delivery wearable injectors.

The U.S. wearable injectors market, valued at USD 3 billion in 2024, is poised for substantial growth. The rising incidence of chronic diseases such as diabetes, obesity, and arthritis is driving demand for self-administration drug delivery systems. The integration of smart technologies in wearable injectors is revolutionizing patient care by enabling real-time monitoring and remote adherence tracking. As healthcare providers prioritize patient-centric solutions, the demand for intelligent and connected drug delivery devices continues to rise. With pharmaceutical and medtech companies investing in cutting-edge innovations, the U.S. market is expected to play a pivotal role in shaping the future of wearable injectors on a global scale.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing incidence of chronic conditions
    • 3.2.1.2 Shift towards home-based healthcare
    • 3.2.1.3 Increasing demand for biologics
    • 3.2.1.4 Patient preference for minimally invasive devices
    • 3.2.1.5 Global aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of wearable injectors
    • 3.2.2.2 Technical and design challenges
• 3.3 Growth potential analysis
• 3.4 Technological advancements
• 3.5 Regulatory landscape
• 3.6 Comparative analysis: patient preferences for handheld autoinjectors Vs wearable large-volume injectors
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 On-body injectors
• 5.3 Off-body injectors

Chapter 6 Market Estimates and Forecast, By Device Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Programmable wearable injectors
• 6.3 Non-programmable wearable injectors

Chapter 7 Market Estimates and Forecast, By Injection Delivery Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Programmed delivery
• 7.3 Bolus delivery

Chapter 8 Market Estimates and Forecast, By Usage Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Disposable wearable injectors
• 8.3 Reusable wearable injectors

Chapter 9 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Spring-based
• 9.3 Motor-driven
• 9.4 Expanding battery
• 9.5 Rotary pump
• 9.6 Other technologies

Chapter 10 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Diabetes
• 10.3 Cardiovascular disease
• 10.4 Oncology
• 10.5 Autoimmune disease
• 10.6 Infectious disease
• 10.7 Other applications

Chapter 11 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 Home care settings
• 11.3 Hospitals and clinics
• 11.4 Ambulatory surgical centers

Chapter 12 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Netherlands
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 South Korea
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Argentina
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 UAE

Chapter 13 Company Profiles

• 13.1 Amgen
• 13.2 Bayer
• 13.3 Becton Dickinson (BD)
• 13.4 CeQur
• 13.5 Eli Lilly and Company
• 13.6 Enable Injections
• 13.7 Eoflow
• 13.8 Gerresheimer
• 13.9 Insulet
• 13.10 Medtronic
• 13.11 novo nordisk
• 13.12 Roche
• 13.13 TANDEM Diabetes Care
• 13.14 Valeritas
• 13.15 West
• 13.16 Ypsomed Selfcare Solutions